Walleye Capital
ROIV icon

Walleye Capital’s Roivant Sciences ROIV Stock Holding History

Walleye Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$501K Sell
18,100
-36,100
-67% -$927K ﹤0.01% 2667
2025
Q4 		$1.18M Buy
54,200
+41,000
+311% +$809K ﹤0.01% 2306
2025
Q3 		$200K Buy
13,200
+4,500
+52% +$55.7K ﹤0.01% 3316
2025
Q2 		$98K Buy
+8,700
New +$94.3K ﹤0.01% 3781
2025
Q1 		– Sell
-5,200
Closed -$61.5K – 5011
2024
Q4 		$61.5K Sell
5,200
-1,600
-24% -$18.9K ﹤0.01% 4303
2024
Q3 		$78.5K Sell
6,800
-32,100
-83% -$365K ﹤0.01% 4496
2024
Q2 		$411K Buy
38,900
+38,800
+38,800% +$425K ﹤0.01% 3672
2024
Q1 		$1.05K Sell
100
-7,400
-99% -$79.8K ﹤0.01% 5317
2023
Q4 		$84.2K Buy
+7,500
New +$73.1K ﹤0.01% 4120

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ROIV Position: Q1 2026 in Review

Walleye Capital increased its Roivant Sciences (ROIV) stake by 211% in Q1 2026, buying an estimated $2.69M and bringing the position to 154,083 shares worth $4.27M. The position accounts for 0.02% of the portfolio, ranked #902.

Walleye Capital first reported a position in ROIV in Q4 2023 and has held it in 6 quarters since. The position peaked at $5.3M in Q4 2023. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Walleye Capital held 154,083 shares of Roivant Sciences worth $4.27M as of Q1 2026.
  • Walleye Capital bought 104,593 Roivant Sciences shares in Q1 2026, an estimated $2.69M.
  • Roivant Sciences made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #902 holding.
  • Walleye Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 6 quarters since.
  • Walleye Capital's Roivant Sciences position peaked at $5.3M in Q4 2023.
  • 439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.